

1 Health System Determinants of Hypertension Care and Outcomes in Sub-Saharan Africa: A
2 Systematic Review

3
4 Samuel Byiringiro^{1*}, Oluwabunmi Ogungbe¹, Yvonne Commodore-Mensah^{1,2}, Khadijat
5 Adeleye³, Fred Stephen Sarfo^{4,5}, Cheryl R. Himmelfarb^{1,2}

6
7 ¹Johns Hopkins University School of Nursing, Baltimore, Maryland, United States

8 ²Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland,
9 United States

10 ³University of Massachusetts, Amherst, MA, USA

11 ⁴Kwame Nkrumah University of Science & Technology, Department of Medicine, Kumasi,
12 Ashanti Region, Ghana

13 ⁵Komfo Anokye Teaching Hospital, Kumasi, Ashanti Region, Ghana

14
15 ***Corresponding Author:**

16 **Email:** sbyirin1@jhu.edu (SB)

17 **Abstract**

18 **Background:** Hypertension is a significant global health problem, particularly in Sub-Saharan
19 Africa (SSA). Despite the effectiveness of medications and lifestyle interventions in reducing
20 blood pressure, shortfalls across health systems continue to impede progress in achieving optimal
21 hypertension control rates. The current review explores health system factors contributing to
22 hypertension outcomes in SSA.

23 **Methods:** The World Health Organization health systems framework guided the literature search
24 and discussion of findings. We searched PubMed, CINAHL, and Embase databases for studies
25 published between January 2010 and June 2022 and followed the Preferred Reporting Items for
26 Systematic Reviews and Meta-Analyses guidelines. We assessed studies for risk of bias using the
27 tools from Joanna Briggs Institute.

28 **Results:** Thirty-nine studies clustered in 10 SSA countries met inclusion criteria. Health system
29 determinants included human resource factors such as providers' knowledge and adherence to
30 hypertension treatment guidelines (n=21) and task sharing and shifting strategies (n=10). The
31 second health system factors explored in service delivery were the health facility type and
32 capacity (n=7) and hypertension service accessibility by cost, place, and time of services (n=15).
33 A quarter of the included studies explored supply chain management for access to essential
34 equipment and medicines. An additional set of studies addressed quality improvement strategies
35 involving cross-integration of services (n=7) and various strategies of gauging the systems for
36 better hypertension outcomes (n=8).

37 **Conclusion:** A combination of multiple rather than solo system interventions may yield
38 significant improvements in blood pressure outcomes. Health information management and
39 leadership involvement were less explored. Additional research on health system determinants of

40 hypertension is needed to drive global improvements in hypertension outcomes. Future research
41 would benefit from more rigorous implementation type interventional studies comprehensively
42 assessing health system factors that contribute to better hypertension outcomes.

43 **Keywords:** hypertension, high blood pressure, raised blood pressure, Sub-Saharan Africa, Low-
44 and Middle-Income Countries, health system, health facilities, quality improvement, quality of
45 care

46

47

48 **Introduction**

49 Hypertension remains a global health challenge, especially for low- and middle-income countries
50 (LMICs) in Sub-Saharan Africa (SSA) [1]. Hypertension is a significant risk factor for stroke
51 and ischemic heart disease, the world's deadliest maladies [2]. It is estimated that 30% of the
52 SSA population have hypertension [3–5], 27% are aware of their hypertensive status, and only
53 7% have their hypertension under control [3]. The prevalence of hypertension in SSA will likely
54 continue to rise due to the rapid shift to sedentary lifestyles, growing urbanization, and a higher
55 number of people living longer [6, 7]. The level of preparedness of health systems for managing
56 hypertension and related sequelae is poor and requires urgent attention [8, 9].

57 Several strategies have been implemented to manage hypertension in SSA. Population-based
58 interventions such as educational campaigns to improve dietary practices by reducing salt
59 consumption have proven cost-effective in lowering blood pressure among hypertensive patients
60 [10–13]. Alternative interventions implemented to reduce dietary salt include increasing the
61 availability and affordability of healthy foods and reformulation of processed foods with the help
62 of government policies [10]. Other strategies including technology and non-technology based
63 reminders targeted the hypertensive patients to improve their adherence to the prescribed
64 pharmacologic and non-pharmacologic treatments [13, 14]. Despite the numerous, effective
65 interventions targeting the patients with hypertension, the health systems are not equipped to
66 provide the best quality care, yet, the health system is the current epicenter in the population-
67 based hypertension [8, 9].

68 Multiple guidelines exist for screening, diagnosing, and treating hypertension [2, 15, 16]. The
69 Pan-African Society of Cardiology task force convened in 2014 laid the roadmap to achieving
70 25% blood pressure control in Africa by 2025[17]. In 2021, the World Heart Federation laid an

71 updated roadmap that identified the major roadblocks in hypertension diagnosis and management
72 and recommended solutions for reducing uncontrolled hypertension by 30% by 2030 [18]. The
73 lack of local hypertension treatment guidelines, protocols, and policies on the procurement and
74 distribution of anti-hypertensives are some of the multiple identified government and health
75 system roadblocks to achieving hypertension control goals [17, 18]. These roadblocks likely
76 result in the lack of community sensitization on hypertension and service inaccessibility through
77 high-cost and centralized hypertension care [19, 20]. According to the Chronic Care Model, the
78 health systems' role in hypertension management should be to support patients for self-
79 management at home, set up systems to ensure patients follow up after clinical encounters, and
80 decentralize hypertension care closest to patients [20, 21]. Health systems should provide access
81 to specialists if needed, ensure providers are trained and have access to the latest guidelines and
82 decision support, and document care to improve the quality of care [20, 21].

83 The World Health Organization (WHO) health systems framework highlights six critical
84 elements to target while working to improve the quality of health services. These are the service
85 delivery; health workforce; access to equipment, consumables, and technology; information
86 systems; financing; and leadership and governance. In 2013, the WHO developed the Service
87 Availability and Readiness Assessment (SARA) to map the progress in the six elements of the
88 health systems[22]. The SARA tool has been extensively utilized in maternal and reproductive
89 health and on a minimal basis in cardiovascular health care [23, 24]. The evidence on the health
90 system determinants of hypertension care and outcomes is limited. The current review
91 synthesizes the literature on the health system factors of hypertension care in SSA and identifies
92 the gaps and opportunities for improving the quality of hypertension care.

93 **Methods**

94 **Search Strategy:**

95 Collaborating with a scientific library informationist, we defined the search terms for
96 hypertension service availability and delivery guided by the WHO health systems' framework
97 [25]. We Identified Medical Subject Headings (MeSH) terms ("Health Facilities," "Health
98 Services Accessibility," "Health Care Delivery"); and hypertension ("hypertension" or "elevated
99 blood pressure" or "raised blood pressure" or anti-hypertensive) in SSA. We searched PubMed,
100 Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Embase. The detailed
101 list of search terms is in Supplementary File 1 (S-File 1).

102

103 **Study selection and eligibility**

104 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [26]
105 guided this systematic review (S-File 2). We imported articles from the literature search into
106 Covidence, and three investigators (SB, KA, and OO) conducted the title and abstract screening,
107 full-text review, and final extraction. Two investigators appraised each article independently at
108 each step, and the third investigator resolved any conflicts. Occasionally, the investigators
109 discussed with the supervising faculty (YCM and CRH) to resolve disputes.

110 In the article search and screening, we included studies (1) published between January 2010 –
111 June 2022; (2) conducted in health facility settings (hospitals, clinics, community health
112 facilities) in SSA; (3) with randomized controlled trials, quasi-experimental, cohort study, case-
113 control study, cross-sectional study designs, and quality improvement projects; (5) which
114 explored the association between healthcare system factors and hypertension awareness,
115 treatment initiation and adherence, and control. The delineation of the search to 2010 was

116 influenced by another systematic review conducted in 2013 exploring the influence of the health
117 system on hypertension awareness, treatment, and control in LMICs [27].

118 We excluded studies (1) merely describing the prevalence of hypertension and associated
119 patient-level factors, (2) which investigated the health system interventions without exploring
120 association with any of the listed hypertension outcomes, and (3) which explored hypertension
121 care interventions conducted solely in the community setting without describing collaboration
122 with health facilities, or (3) examining patient-level behavioral change interventions for
123 hypertension management. Additionally, we excluded gray literature (books, cases, etc.).

124 The investigators tracked the rationale for excluding any study during the entire process
125 following the article search as reported in the PRISMA flowchart (Figure 1).

126 **[Insert Figure 1]**

127 **Risk of Bias Assessment**

128 We used the Joanna Briggs Institute (JBI) tools to assess the quality aspects of the methods and
129 conduct of the studies included in the review [28]. We evaluated the quality improvement study
130 using the Standards for Quality Improvement Reporting Excellence 2.0 (SQUIRES) guideline
131 [29]. SQUIRES uses a checklist of standard elements for reports of system-level projects to
132 improve healthcare quality. Two investigators independently assessed the risk of bias for each
133 study and the third resolved conflicts. The JBI tool uses "Yes," "No," and "Unclear or Not
134 applicable" to assess the different features of study design and the overall appraisal as include
135 study, exclude study, or seek more information. We replaced "Yes," "No," and "Unclear" with
136 "Low risk of bias," high risk of bias," and "Some concerns," respectively. We assigned the
137 overall quality appraisal of each study as "good," "fair," and "poor" and studies with poor quality
138 were excluded. We used the robvis [30] online tool to create risk-of-bias plots where the overall

139 appraisal was also converted to "low risk of bias" for the study of good quality, "some concerns"
140 for studies of fair quality and "high risk of bias" for studies of poor quality.

141 **Analysis and synthesis of findings**

142 After the data extraction, we identified relevant themes of health system factors and interventions
143 for hypertension care. We classified the outcomes of each study in the appropriate group:
144 hypertension awareness, systolic and diastolic blood pressure (BP), treatment initiation and
145 adherence, and BP control. We tracked which factors/interventions are likely to lead to better
146 hypertension outcomes and compared findings across the different countries of SSA. We
147 discussed the results against the other potential areas of health systems crucial to improving the
148 quality of hypertension care as delineated in the WHO health systems framework [25].

149 **Results**

150 We identified 7,494 studies, yet 3,121 were duplicates (Figure 1). We conducted title and
151 abstract screening for 4,373 studies yielding 205 for full-text review. The latter led to 39 studies
152 for inclusion in this systematic review (Table 1). The quality assessment demonstrated a low risk
153 of bias in 62% (24/39) of the included studies (S-File 3). Given the nature and complexity of
154 health system interventions, the compliance to all requirements of the study design raised some
155 concerns in 38% (15/39) of the included studies. Among randomized controlled trials, the most
156 common issues were the lack of concealed intervention allocation, the similarity of groups at
157 baseline, and blinding participants and those delivering the intervention of the group
158 assignments. The most common concern among cohort studies was the lack of identification and
159 management of confounding factors and strategies to address participants' loss to follow-up. The
160 identification and management of confounding factors was the most common reason for concern
161 among cross-sectional studies.

162 **Fig 1. PRISMA diagram with flowchart of study screening and inclusion]**
163

Table 1. characteristics of studies examining the association between health system factors or interventions and hypertension outcomes (N=39)

Study	Country	Study Design	Population and Sample size	Health system factors/interventions explored							
				HF	PD	AC	TS	QC	SC	SI	
Adedapo, 2012[1]	Nigeria	Cross-sectional study	116 patients with hypertension			*					
Adomako, 2021[2]	Ghana	Cross-sectional study	485 patients with hypertension aged 25 to 80			*				*	
Akunne, 2019 [3]	Nigeria	Cross-sectional study	1050 black patients with hypertension		*						
Ambaw, 2012 [4]	Ethiopia	Cross-sectional study	384 patients with hypertension			*					
Ameh, 2020 [5]	South Africa	Cross-sectional study	878 patients receiving treatment for HIV, hypertension, and diabetes in 12 health facilities in South Africa in 2011					*		*	
Asgedom, 2018 [6]	Ethiopia	Cross-sectional study	311 patients with hypertension			*					
Berhe, 2017 [7]	Ethiopia	Retrospective Cohort	897 patients with hypertension	*							
Birungi, 2021 [8]	Tanzania and Uganda	Cohort study	2640 adults (18 years & older) with documented HIV infection and a diagnosis of either diabetes or hypertension or both		*					*	
Gala, 2020 [9]	Botswana	Cross-sectional study	389 patients with hypertension attending seven public health facilities	*	*					*	
Gausi, 2021 [10]	South Africa	Cohort study	247 adults (18 years & older) with documented HIV infection and a diagnosis of either diabetes or hypertension or both								
Goudge, 2018 [11]	South Africa	Cluster Randomized Controlled Trial	3978 patients at baseline receiving care at eight community health clinics		*		*				
Harrison, 2021 [12]	Ghana	Cross-sectional study	310 patients with hypertension			*					
Hendriks, 2014 [13]	Nigeria	Quasi-experimental study	1500 patients with hypertension			*					
Hickey, 2021 [14]	Kenya and Uganda	Randomized controlled trial	86,078 adults with uncontrolled hypertension		*	*	*				
Kachimanga, 2021 [15]	Sierra Leone	Cohort study	982 with a new or prior hypertension or diabetes mellitus diagnosis		*						
Kande, 2014 [16]	Botswana	Quality improvement project	233 people from the general population attending the health clinic					*		*	
Kingue, 2013 [17]	Cameroon	Randomized controlled trial	268 patients with hypertension who receive care at 30 health clinics		*			*			
Kuria, 2018 [18]	Kenya	Cross-sectional study	3861 patients with hypertension			*					
Labhardt, 2010 [19]	Cameroon	Pre- and post-quasi-experimental	79 primary health facilities		*		*	*		*	
Lulebo, 2017 [20]	Congo (Democratic Rep.)	Cross-sectional study	260 patients with hypertension at five general referral hospitals and nine health centers	*				*			
Mashozhera, 2021 [21]	Namibia	Cross-sectional study	189 elderly patients (aged 60years and above), diagnosed with hypertension and on antihypertensive therapy		*			*			
Mbau, 2022 [22]	Kenya	Cross-sectional study	663028adults (18 years & older)	*							
Mekonnen, 2017 [23]	Ethiopia	Cross-sectional study	409 adult patients>18 years with hypertension			*					
Menyanu, 2021 [24]	Ghana	Cross-sectional study	820 adults of 50 years and above with self-reported hypertension status			*					
Miselli, 2021 [25]	Tanzania	Cohort study	542 adults (18 years & older) with hypertension								
Mlawanda, 2014 [26]	Eswatini	Cross-sectional study	60 adult patients>18 years with/out hypertension		*						
Nelissen, 2018 [27]	Nigeria	Pre- and post-quasi-experimental	336 adult patients with hypertension receiving medications at community pharmacies		*	*	*				
Ogedegbe, 2018 [28]	Ghana	Pragmatic randomized trial	640 patients with hypertensive and being followed at community health clinics		*	*	*				

Study	Country	Study Design	Population and Sample size	Health system factors/interventions explored						
				HF	PD	AC	TS	QC	SC	SI
Ogola, 2019 [29]	Kenya	Quasi-experimental study	132 health facilities		*			*	*	
Otieno, 2021 [30]	Ghana and Kenya	Cohort Study	1266 patients with hypertension at nine health facilities		*	*	*			
Pfister, 2020 [31]	South Africa	Cross-sectional study	106 adults admitted for elective surgery		*			*		
Pillay, 2021 [32]	South Africa	Prevalence study		*						
Ratnayake, 2021 [33]	Congo (Democratic Republic of)	Cohort study	833 adults	*	*				*	
Sarfo, 2020 [34]	Ghana	Cross-sectional study	3927 stroke survivors with/out hypertension	*						
Sharp, 2020 [35, 36]	Eswatini	Prevalence study	1125 patients attending community clinics		*	*	*			
Steyn, 2013 [36]	South Africa	Cluster Randomized Controlled Trial	920 patients with hypertension					*		
Vedanathan, 2020 [37]	Kenya	Cohort study	1051 adults with hypertension		*	*	*		*	
Yan, 2017 [38]	Zambia	Randomized stepped wedge design	35052 patients with hypertension		*		*	*	*	
Zou, 2020 [39]	Sierra Leone	Quasi-experimental – Mixed Methods	50 persons with hypertension and diabetes diagnosis		*		*		*	

Abbreviations: **HF** - Health facility type & capacity; **PD** - Provider knowledge and decision support; **AC** - Accessibility of care (cost, location, and time of services); **TS** - Task sharing/ shifting strategy; **QC** - Quality of care (deliberate improvement in care systems); **SC** - Supply chain (availability of essential equipment and consumables); **SI** - Services' cross-integration

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.19.22280830>; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

5
6
7
8

169 **Country and design of included studies**

170 Of the 39 included studies, six were randomized controlled trials conducted in South Africa
171 (n=2) [31, 32], Cameroon (n=1) [33], Ghana (n=1) [34], Kenya and Uganda (n=1) [35], and
172 Zambia (n=1) [36]. Five quasi-experimental studies were conducted in Nigeria (n=2)[37, 38],
173 Cameroon (n=1) [39], Kenya (n=1) [40], and Sierra Leone (n=1) [41]. Eight cohort studies were
174 conducted in Ethiopia (n=1) [42], Uganda and Tanzania (n=1) [43], Tanzania (n=1) [44], South
175 Africa (n=1) [45], Sierra Leone (n=1) [46], Ghana and Kenya (n=1) [47], Kenya (n=1) [48], The
176 Democratic Republic of the Congo (n=1) [49].
177 Nineteen cross-sectional studies were conducted in Ethiopia (n=3) [50–52], Nigeria (n=2) [53,
178 54], Botswana (n=1) [55], Democratic Republic of Congo (n=1) [56], Swaziland now called
179 Eswatini (n=2) [57, 58], Namibia (1) [59], South Africa (n=3) [60–62], Ghana (n=4) [63–66] ,
180 Kenya (n=2) [67, 68]. We additionally identified one quality improvement report from Botswana
181 [69]. The geographic representation of included studies by country is demonstrated in Figure 2.

182
183 **Fig 2. Distribution of studies on health system factors of hypertension care in Sub-Saharan**
184 **Africa**

185 186 **Health system factors and interventions explored**

187 The most studied health system factors were human resource factors – (1) healthcare providers'
188 knowledge and adherence to hypertension treatment guidelines and decision support systems;
189 and (2) the task-sharing/shifting of hypertension care tasks to unconventional health
190 professionals. Other health system factors related to service delivery included (3) the health
191 facility type and capacity and (4) service accessibility in terms of cost, place, and time of care
192 (Table 2). Additionally, studies explored (5) supply chain management for access to essential
193 equipment and anti-hypertensive medicines. Finally, studies explored the revision of the patient

194 care process at the health facility through (6) the cross-integration of services and (7) the
 195 different quality improvement strategies for improving hypertension care.

196 **Table 2. Health system factors and interventions explored and corresponding countries**
 197 **where they were conducted**

Health system factor/interventions	Number of studies	Country (number of studies)
Health facility type and capacity	7	Ethiopia (1), Botswana (1), Democratic Republic of the Congo (2), Kenya (1), South Africa (1), Ghana (1)
Provider knowledge and decision-support	20	Nigeria (2), Tanzania (1), Uganda (2), Botswana (1), South Africa (2), Kenya (4), Sierra Leone (2), Cameroon (2), Namibia (1), Eswatini (1), Democratic Republic of the Congo (1), Zambia (1)
Accessibility of care (cost, location, and time of services)	15	Ethiopia (3), Ghana (4), Kenya (3), Nigeria (3), Eswatini (1), Kenya and Uganda (1)
Task-sharing/shifting strategy	10	South Africa (1), Kenya and Uganda (1), Cameroon (1), Nigeria (1), Ghana and Kenya(1), Ghana (1), Kenya (1), Eswatini (1), Zambia (1), Sierra Leone (1)
Quality of care (deliberate improvement of care systems)	10	South Africa (3), Botswana (1), Cameroon (2), Democratic Republic of the Congo (1), Namibia (1), Kenya (1), Zambia (1)
Supply chain (availability of essential equipment and consumables)	10	Ghana (1), South Africa (1), Botswana (2), Cameroon (1), Kenya (2), Democratic Republic of the Congo (1), Zambia (1), Sierra Leone (1)
Services cross-integration	8	South Africa (3), Tanzania and Uganda (1), Kenya and Uganda (1), Sierra Leone (1), Tanzania (1), Democratic Republic of the Congo (1)

198 Note: Some studies reported more than one system factor

199

200 **(1) Healthcare providers' knowledge and adherence to hypertension treatment**
 201 **guidelines and decision support system**

202 Half of the studies (21/39) [32–36, 38–41, 43, 46–49, 53, 55, 57–59, 61] across 13 countries

203 explored the impact of healthcare provider knowledge of or adherence to hypertension treatment

204 guidelines and decision support system on hypertension outcomes (Table 3). Generally, higher

205 provider knowledge of or better adherence to guidelines and availability of decision-making

206 support systems correlated with better hypertension care outcomes. For instance, the lack of

207 physician knowledge in prescribing anti-hypertensives at a University College Hospital in

208 Nigeria demonstrated 76% higher or lower blood level doses (as measured in urine) of anti-

209 hypertensives than recommended and contributed to 35% lower BP control [53]. Adherence to
210 the Eighth Joint National Committee guidelines contributed to 46% of additional patients
211 achieving BP control in Kenya [70]. An approximately similar pattern was observed in a study
212 conducted in Botswana [55].

3 **Table 3. Studies examining the association between health system factors or interventions and hypertension outcomes (N=39)**

Study	Country	Study Design	Health system factors							Outcomes and key findings				
			H F	P D	A C	T S	Q C	S C	S I	Hypertension awareness	Systolic/diastolic BP	Hypertension treatment (initiation and adherence to-)	BP Control	
Adedapo, 2012[1]	Nigeria	Cross-sectional			*					NR	NR	NR	After another cross-sectional study published in 2003 (n=114), a co-payment policy was implemented. Patients with full control of hypertension increased from 38% to 70% despite the co-payment policy.	
Adomako, 2021[2]	Ghana	Cross-sectional			*				*	NR	NR	NR	Receiving 70-100% of drugs from the hospital was associated with 55% hypertension control vs. 31% when receiving less than 69% at University Health Service and 49% vs. 44% at Komfo Anokye Teaching Hospital.	
Akunne, 2019 [3]	Nigeria	Cross-sectional		*						NR	The higher number of drugs prescribed correlated positively with the increase in systolic and diastolic blood pressure (r=0.25 and 0.18 respectively, p<0.001) and	NR	Overall BP control was 35%	
Ambaw, 2012 [4]	Ethiopia	Cross-sectional			*					NR	NR	Patients who travel for less than 30 minutes to the hospital had 2.02 times higher odds of adherence than their counterparts who travel for 30 minutes or more (95% CI: 1.19-3.43). The cost associated with adherence was not reported	NR	
Ameh, 2020 [5]	South Africa	Cross-sectional study						*	*	*	NR	NR	NR	The pilot facilities had a 3.6% greater chance of controlling BP than the comparison facilities during the 24 months of implementation of the ICDM model (coef. = 0.036; 95% CI: 0.029, 0.043; P<0.001).
Asgedom, 2018 [6]	Ethiopia	Cross-sectional			*					NR	NR	Patients who reported paying a fee for medications were 50 times more likely to be non-adherent to the medications than the patients who received medications for free (aOR = 0.020, 95% CI = 0.003–0.117, p < 0.001)	NR	
Berhe, 2017 [7]	Ethiopia	Cohort	*							NR	NR	NR	242/363 (60%) achieved BP control in general as opposed to 93/199 (32%) in follow-up at the specialized clinics. The adjusted odds of BP control were 1.89 (95% CI 1.26 to 2.83) in general hospitals compared to specialized hospitals.	
Birungi, 2021 [8]	Tanzania and Uganda	Cohort		*						NR	Mean (range) Systolic BP at baseline - 144.7 mmHg (68.7, 271.0); and 135.4 mmHg (26, 228) at end-line. Mean (range) diastolic BP at baseline - 90.2 (43.3–167.3) to 84.8 (44–185) mmHg at end-line.	NR	Baseline - 416 (38.3%); Endline - 476 (53.9%). Risk difference of uncontrolled hypertension (endline minus baseline) was 14.8% (10.5% to 19.2%; p<0.001); and 10.5% (5.7% to 15.3%; p<0.001) among people who were retained in care for more than 6 months	

Study	Country	Study Design	Health system factors								Outcomes and key findings			
			H F	P D	A C	T S	Q C	S C	S I	Hypertension awareness	Systolic/diastolic BP	Hypertension treatment (initiation and adherence to-)	BP Control	
Gala, 2020 [9]	Botswana	Cross-sectional	*	*					*		NR	NR	NR	Compared to the health posts, community clinics were three times more likely to have patients with uncontrolled hypertension (AOR=3.02 95% CI 1.35-6.73, p=0.007). Compared to the health post, the hospital clinic had the adjusted odds of uncontrolled BP of 0.90 (p=0.791). Medication errors were associated with 3.26 times higher odds of uncontrolled BP (95% CI 1.75-6.06 p<0.001).
Gausi, 2021 [10]	South Africa	Cohort							*		NR	Mean systolic BP one year before integrated care: 139.9 mmHg (95% CI 136.9, 142.9 mmHg); at entry to integrated care: 132.1 mmHg (95% CI 129.7, 134.6 mmHg); one year after integrated care: 136.7 mmHg (95% CI (133.7, 139.6 mmHg). Mean diastolic BP 80.1 mmHg [95% CI (78.4, 81.9 mmHg)] at 1-year post-IC enrolment. Increasing diastolic BP 1-year post-Integrated Care enrolment compared to integrated care entry was not statistically significant (p=0.370).	Mean medication adherence before and after Integrated Care: 92.2% and 94.2% (p:0.223)	One year before integrated care - 43.4%; at integrated care entry, 58%; and at one-year post integrated care - 49.4%.
Goudge, 2018 [11]	South Africa	RCT		*		*					There was no statistically significant difference awareness comparing intervention and control groups.	NR	NR	There was no statistically significant difference in BP control comparing intervention and control groups.
Harrison, 2021 [12]	Ghana	Cross-sectional			*						NR	NR	NR	Affordability of care was associated with hypertension control (OR, 1.917; 95% CI: 1.013-3.630), and coverage of medications by the National Health Insurance Scheme (NHIS) was more likely to result in hypertension control than out-of-pocket only or NHIS plus out-of-pocket payment (OR, 2.185; 95% CI 1.215-3.927). Patients' access to anti-hypertensive medications at the hospital was more likely to result in hypertension control (OR, 1.642; 95% C.I., 0.843-3.201).
Hendriks, 2014 [13]	Nigeria	Quasi-experimental			*						From baseline to end-line, there was no significant difference in hypertension awareness between intervention and control settings.	NR	From baseline to end-line, there was no significant improvement in patients' initiation of treatment in the intervention compared to the control settings (aOR: 1.37; p=0.69).	There was no significant improvement in the number of people achieving controlled BP in the program area compared to the control area. AOR 3.16 (95% CI 0.78 to 12.79 p=0.11).

Study	Country	Study Design	Health system factors								Outcomes and key findings			
			H F	P D	A C	T S	Q C	S C	S I	Hypertension awareness	Systolic/diastolic BP	Hypertension treatment (initiation and adherence to-)	BP Control	
Hickey, 2021 [14]	Kenya and Uganda	RCT		*	*	*				*	Likelihood of patients linked to hypertension care following baseline screening (aRR 1.26; p:0.002, 95% CI 1.11, 1.42)	NR	NR	56% of intervention group participants and 43% of control group participants achieved hypertension control at year 3 (aRR 1.29; p < 0.001, 95% CI: 1.03 - 1.63)
Kachima nga, 2021 [15]	Sierra Leone	Cohort		*						*	NR	NR	NR	Hypertension control among patients with hypertension was 6% at baseline and 31% at follow-up (p<0.001). Among patients with comorbidity of diabetes mellitus: 10% at baseline to 28% at follow-up (p<0.01)
Kande, 2014 [16]	Botswana	Quality improvement project						*	*		NR	NR	NR	The goal of achieving 70% BP control from 49% at baseline was met, but achieving BP control below 130/80mmHg of 70% from 16% at baseline was not met (27% at end-line). Patients with the third stage of hypertension showed significant achievement of BP control in the intervention compared to control health facilities (39% vs. 50%; p= 0.004). There was no significant difference in BP control for patients with hypertension stages I and II.
Kingue, 2013 [17]	Cameroon	RCT		*				*			NR	NR	NR	
Kuria, 2018 [18]	Kenya	Cross-sectional			*						NR	NR	NR	Self-reported adherence to hypertension medications was 96% walkway, 94% facility, and 88% weekend. The logistic regression analysis showed that the OR of adherence to medications was 1.97 in walkway compared to health facility (95% CI 1.25-3.10), and those for the weekend were 76% times less likely to adhere to medications (AOR 0.24, 95% CI 0.10-0.57)
Labhardt, 2010 [19]	Cameroon	Quasi-experimental		*		*	*	*			NR	There was a decline of -26.5 mmHg (95% CI: -12.5 to -40.5) in systolic BP and -17.2 mmHg (95% CI: -7.1 to -27.3) in diastolic BP after full adjustment (comparing baseline and end-line after a median follow up of 3 months)	NR	NR
Lulebo, 2017 [20]	The Democratic Republic of the Congo	Cross-sectional	*								NR	NR	NR	22% vs. 23% achieved BP control in general referral vs. health center, respectively, but the difference in BP control was not statistically significant. Eighteen percent of patients reported getting insufficient time with health care providers at the health centers compared

Study	Country	Study Design	Health system factors								Outcomes and key findings			
			H F	P D	A C	T S	Q C	S C	S I	Hypertension awareness	Systolic/diastolic BP	Hypertension treatment (initiation and adherence to-)	BP Control	
Mashozhera, 2021 [21]	Namibia	Cross-sectional		*							NR	NR	NR	to 3% at the general referral hospitals. This difference was not reflected in the difference in achieving BP control. Compliance with Namibia Standard Treatment Guidelines was associated with 1.2 (p=0.571; 95% CI 0.7,2.1) crude odds of BP control. <i>Note: There is universal healthcare in Namibia; consequently, patients do not have to pay for their anti-hypertensive medicines compared with several African countries.</i>
Mbau, 2022 [22]	Kenya	Cross-sectional		*							Screening of hypertension comparing different levels of the health system - Community services screened 489,973 people - 19% prevalence - reference; Dispensary: screened 12,460 - 16.3% (PR: 0.85, 95% CI: 0.81, 0.88); Health centers screened 103,103 - 13.6% (PR: 0.70, 95% CI: 0.69, 0.72); Sub-county health facilities screened 50786 - 22.4% (PR: 1.16, 95% CI: 1.14, 1.18); county referral hospital screened 6706 - 30.4% (PR: 1.57, 95% CI: 1.51, 1.63)	NR	Patient initiation on treatment was as follows: The dispensary - 5.3%; health center - 25.6%; sub-county hospital - 32.9%; and county referral hospital - 36.2%. Overall retention on treatment was 31% at six months and 12% at 12 months.	BP control was as follows: Dispensary- 53% (Ref); Health centers: 47% - (0.89, 95% CI: 0.78 - 1.00); Sub- County hospital: 48% -(0.92, 95% CI: 0.76 - 1.11); county referral hospital: 60% - (1.1, 95% CI: 0.92-1.32)
Mekonnen, 2017 [23]	Ethiopia	Cross-sectional			*						NR	NR	130 Patients (44%) reported paying below 50 birrs (1.5 USD) a month and were two times more likely to adhere to medications compared to those who spent 50 birrs or more (aOR 2.02; p:<0.05; 95% CI 1.13-3.76).	NR
Menyanu, 2021 [24]	Ghana	Cross-sectional			*						The odds of hypertension awareness among people with vs. without health insurance: 1.99 (p: 0.008; 95 %CI 1.19-3.33).	Patients with health insurance had a 2.60 (p: 0.037; 95 % CI - 5.03 - (-0.16)) mmHg decline in diastolic BP than patients without health insurance	NR	NR
Miselli, 2021 [25]	Tanzania	Cohort study			*						NR	NR	Lost to follow-up for hypertension care - without health insurance - 202/351, 57.5% vs. with health insurance 86/190, 45.3%, p= 0.008.	Achieving BP control was more frequent in patients with compared to those without health insurance (46/84, 54.8% vs. - 43/124, 34.7%, p= 0.006)
Mlawanda, 2014 [26]	Eswatini	Cross-sectional		*							NR	NR	(9/60) 15% of patients were classified as requiring initiation or modification of treatment under	NR

Study	Country	Study Design	Health system factors								Outcomes and key findings			
			H F	P D	A C	T S	Q C	S C	S I	Hypertension awareness	Systolic/diastolic BP	Hypertension treatment (initiation and adherence to-) pragmatic (real life) BP measurement conditions vs. not requiring treatment under standard mercury BP measurement.	BP Control	
Nelissen, 2018 [27]	Nigeria	Quasi-experimental		*	*	*					NR	NR	Out of 148 who responded to their adherence to medications, 40 patients showed high adherence, and 39 showed moderate adherence.	153 of 232 (66%) who participated in the end-line interviews achieved the target and/or improvement in BP. Of those who showed moderate adherence to medications, 70.9% achieved target BP (aOR 1.57 p:0.257), while among patients with high adherence - 75.5% achieved target BP (aOR 2.27 p: 0.049)
Ogedegbe, 2018 [28]	Ghana	RCT		*	*	*					In the intervention group, the mean Systolic BP reduction from baseline to 12 months was 20.4 mm Hg (95% CI: -25.2 to -15.6) as opposed to 16.8 mm Hg (95% CI -19.2 to -15.6) in the control group. The group's difference was significant (-3.6 mm Hg p = 0.021; 95% CI -6.1 to -0.5).	NR	There was no between-group statistically significant difference in achieving hypertension control in 12 months, 55% vs. 50% in the intervention and control, respectively [diff of 5.2%; 95% CI -1.8% to 12.4%].	
Ogola, 2019 [29]	Kenya	Quasi-experimental		*				*	*		532,527 individuals screened for hypertension, and 50,957 were newly diagnosed (prevalence of 9.57%) within one year	NR	Treatment initiation: 36806 of 50957 (72%) were initiated on treatment	NR
Otieno, 2021 [30]	Ghana and Kenya	Cohort		*	*	*					NR	Systolic BP decreased by 9.4 mmHg (p<0.001) within 12 months from baseline.	The proportion of controlled Systolic BP increased from 46% at baseline to 77% at end-line (12 months) (p<0.001)	
Pfister, 2020 [31]	South Africa	Cross-sectional		*				*	*		NR	NR	Patients initiated on treatment or had adjustment of treatment (55.5%; 95% CI, 46.2-65.1).	NR
Pillay, 2021 [32]	South Africa	Cross-sectional	*								Significantly more patients were screened for hypertension at clinics than in hospitals, and the trends of the number of patients screened have increased at both clinics (6.5 to 11 million) and hospitals (approx. 200,000 to 1 million) from 2015 to 2018.	NR	A significantly higher number of patients were diagnosed and initiated on treatment at clinics than in hospitals, and the trends have increased from 36 to 67 thousand patients at clinics and 5 to 10 thousand at hospitals between 2014 and 2018.	NR
Ratnayake, 2021 [33]	Congo (Democratic Republic of)	Cohort	*	*				*	*		Hypertension awareness: IRR of consultations for hypertension: 13.5 (p: 0.00, 95% CI 5.8-31.5).	Mean systolic BP was 133 (SD: 12.7), down from 161.1 (SD: 22.4) mmHg.	220 (34%) of patients with hypertension remained in care; 71.4% of them achieved Systolic BP control;	NR
Sarfo, 2020 [34]	Ghana	Cross-sectional	*								NR	NR	NR	Risk factor of apparent treatment-resistant hypertension among patients with

Study	Country	Study Design	Health system factors								Outcomes and key findings			
			HF	PD	AC	TS	QC	SC	SI	Hypertension awareness	Systolic/diastolic BP	Hypertension treatment (initiation and adherence to-)	BP Control	
													hypertension by health facility type - Secondary/Primary health facilities (reference); Tertiary health facilities: 1.26 (1.00 - 1.58). Risk factor of apparent treatment-resistant hypertension among stroke survivors by health facility type - Secondary/Primary health facilities (reference); Tertiary health facilities: 2.77 (1.41–5.46).	
Sharp, 2020 [35, 36]	Eswatini	Cross-sectional		*	*	*				NR	change in Systolic BP from first to fourth visit was -9.9 (95% CI: -13.2, -6.0; p: 0.01) mmHg and the change in diastolic BP was -4.7 (95% CI: -7.1, -2.3; p: 0.01) mmHg	NR	Systolic BP above 140mmHg at the first and fourth visit was 57% and 39%, respectively, and diastolic BP above 90mmHg decreased from 29% to 18%.	
Steyn, 2013 [36]	South Africa	RCT						*		NR	Increased from 149.7/87.5 to 161/88 mmHg in the intervention as it was in the control group (152/86 to 158/87 mmHg).	NR	In the intervention group, uncontrolled BP increased from 69% to 76%, as it did in the control group from 73% to 74%.	
Vedanathan, 2020 [37]	Kenya	Cohort		*	*	*			*	NR	Change in systolic BP in three months among nurse-managed patients - slope 4.95 mmHg/month; clinical officer-managed patients - slope 5.28), no significant difference between groups. Change in diastolic BP in the first three months - Nurse-managed: slope, 2.37 (95% CI, 3.24 - 1.50); Clinical officer-managed - slope 2.45 (95% CI, 2.38 - 2.07). The difference in slopes was 0.08 (95% CI, 0.87 to 1.02).	NR	The ratio of BP control among Nurses-managed vs. clinical officer-managed patients was 0.80 (95% CI, 0.67 to 0.97).	
Yan, 2017 [38]	Zambia	RCT		*		*	*	*		NR	NR	NR	Hypertension control was 12.9% at six months and plateaued at 25% at 42 months	
Zou, 2020 [39]	Sierra Leone	Quasi-experimental		*		*		*		NR	The average diastolic BP was 98 mmHg at baseline vs. 86 mmHg in three months, t = 4.069, P= 0.001). The average Systolic BP decline was 15 mmHg from 172 mmHg (t = 1.701, p= 0.106).	NR	NR	

Abbreviations: HF - Health facility type & capacity; PD - Provider knowledge and decision support; AC - Accessibility of care (cost, location, and time of services); TS - Task sharing/ shifting strategy; QC - Quality of care (deliberate improvement in care systems); SC - Supply chain (availability of essential equipment and consumables); SI - Services' cross-integration; RCT - Randomized controlled Trial; NR- Not reported; CI – Confidence Interval; aOR – Adjusted Odds Ratio

217 Improvement in the healthcare providers' skills and knowledge of the correct blood pressure
218 measurement techniques and hypertension diagnosis, respectively, were effective in managing
219 hypertension in Kenya [40]. In its first year, the program helped screen 532 527 individuals,
220 diagnose almost 10% of them with hypertension, and initiate 72% of those diagnosed on
221 treatment [40]. The provider skills in BP measurement were assessed in Eswatini by comparing
222 the pragmatic measurements with standard sphygmomanometer measurements [57]. The two
223 measurements showed a good agreement of 0.7 Kappa score and an 84% concurrence in
224 hypertension treatment decisions (continuing, changing, adjusting, stopping treatment).

225 **(2) Task-sharing/shifting strategy**

226 A quarter of studies (10/39) [32, 34–36, 38, 39, 41, 47, 48, 58] conducted in 9 countries explored
227 the impact of delegating some hypertension care tasks to non-physician providers (task-shifting)
228 or community health workers. The task-shifting consisted of training and giving roles to lay
229 community health workers in South Africa [32] and Zambia [36] to conduct and record the BP
230 measurements, to nurses in Cameroon [39] and Ghana [34] to treat hypertension (including
231 prescribing drugs), and to pharmacists in Nigeria [38] to treat hypertension (prescribe
232 medications) and dispense medications after diagnosis at the health facility.

233 The impact of task-shifting varied across studies but bent towards positive BP outcomes. In
234 Ghana [34] and Cameroon [39], task-shifting contributed to the significant decline in systolic and
235 diastolic BP but not in the achievement of controlled BP [34, 39]. On the other hand, in the two
236 quasi-experimental studies conducted in Nigeria and Zambia, respectively, the task-shifting
237 contributed to the achievement of controlled BP in Nigeria (AOR 2.27, p: 0.049) from baseline
238 to end line and in Zambia from 13% at baseline to 25% (no p-value reported) among patients
239 who attended at least 2 follow up visits [36, 38]. In a cluster randomized controlled trial

240 conducted in South Africa, the task-shifting to lay community health workers in BP
241 measurement and documentation contributed to higher adherence to appointments (75% vs. 56%
242 patients attending their assigned appointments) but no statistically significant improvements in
243 achieving BP control comparing the intervention to the control group [32].

244 **(3) Health facility type and capacity**

245 Eighteen percent (7/39) of the included studies [42, 49, 55, 56, 62, 65, 68] explored the impact of
246 health facility type and capacity on hypertension care and outcomes. The studies highlighted the
247 significant yet inconsistent differences in hypertension outcomes associated with receiving care
248 at either community health post (closer to the community - offering one or very few primary
249 healthcare services), community health center (serving a slightly bigger size of the community -
250 offers the whole package of primary care services), general referral hospital, or specialized
251 clinics. In Botswana, community health posts were three times better than community health
252 clinics in helping patients achieve BP control [55]. In Ethiopia, general referral clinics were
253 almost two times better than specialized clinics [42] in patients' achievement of BP control. In
254 the Democratic Republic of Congo, there were no significant differences in BP outcomes
255 between general referral hospitals and community health centers [56]. Additionally, the presence
256 of the doctor on a daily basis (OR:1.64; 95% CI:1.17-2.31; $p=0.004$) and a higher mean number
257 of nurses in the clinic (OR: 1.15; 95% CI:1.08-1.23; $p=0.001$) were significantly associated with
258 BP control at the baseline of a randomized controlled trial conducted in South Africa [71].

259 **(4) Accessibility of hypertension care (cost, geographic, temporality of service delivery)**

260 The effect of patients' access to hypertension care on hypertension outcomes was explored in
261 38% (15/39) of the included studies within seven SSA countries [34, 35, 37, 38, 47, 48, 50–52,
262 54, 58, 63, 64, 66, 67]. The general trend was that the lower cost of care was significantly

263 associated with better hypertension outcomes. The two quasi-experimental studies conducted in
264 Nigeria and Ghana provided health insurance coverage to the intervention group and to both
265 study arms, respectively [34, 37]. In both studies, the systolic and diastolic BP declined in both
266 study arms with a significant and sharper decline in the intervention arms even though the
267 achievement of BP control was not significantly different in the intervention versus control arms.
268 Two cross-sectional studies in Ethiopia reported that patients' payment of user fees was
269 associated with 50 times higher odds of uncontrolled BP while paying less than 50 Ethiopian
270 Birr (approximately 1 USD) was associated with two-fold higher odds of achieving BP control
271 [50, 52].
272 Four studies reported the factors related to the spatial and temporality accessibility of
273 hypertension care services in achieving BP control. The shorter distance to the health facilities
274 [51] and time flexibility at the hypertension care clinics were associated with better hypertension
275 care outcomes [67]. Yet, such patterns were not true in South Africa, where rural dwellers
276 (where people are likely to travel longer to health facilities) were better responders to treatment
277 intensification by achieving BP control compared to urban dwellers (OR: 0.66; 95% CI: 0.45-
278 0.97; p:0.034) [71]. In Ethiopia, traveling less than 30 minutes to the hospital had 2.02 times
279 higher odds of medication adherence compared to traveling 30 minutes or more [51]. Similarly,
280 the flexibility in location (other than at the health facility) and time of day of dispensing
281 medications were associated with better health outcomes, as reported in Kenya [67] and Nigeria.
282 [38] In Kenya, the extension of hypertension service hours to include evening hours led to a two
283 times likelihood of patients' adherence to anti-hypertensive medications even though patients
284 scheduled to attend weekend clinics had 76% fewer odds of medication adherence [67].

285 **(5) Supply chain management for the availability of essential equipment and**

286 **consumables**

287 A quarter (10/39) of the studies [36, 39–41, 48, 49, 55, 66, 67, 69] across eight countries
288 explored the availability of equipment and consumables involved in hypertension management
289 and impact on BP outcomes. The procurement of drugs and consumables and improvement in
290 the supply chain implemented in the experimental studies and quality improvement project was
291 in combination with other interventions such as providers' training in Cameroon, Kenya, and
292 Zambia [36, 39, 40], and better data management in Botswana [69]. In these studies, the impact
293 of the equipment and supply chain was not necessarily isolated but undoubtedly contributed to
294 the overall improvements in BP outcomes.

295 The cross-sectional study conducted in Botswana reported that the medication errors contributed
296 to three times higher odds (Odds Ratio: 3.23; 95% CI 1.75-6.06 $p < 0.001$) of uncontrolled BP.
297 Almost one-third of the errors were dispenser errors caused mainly by the stock out of the
298 medication and reluctance to refer the patients back to the prescriber to provide an alternative
299 medicine [55]. The interventions that showed significant improvement in BP improved not only
300 the availability of the equipment but also the essential anti-hypertensive drugs, as is the case in
301 Kenya [40].

302 **(6) Cross-integration of services**

303 The integration of hypertension and other non-communicable diseases services into the well-
304 established health services was explored in 18% (7/39) of the studies in 6 different countries [35,
305 43, 45, 46, 49, 60, 61]. The most frequent form of cross-integration was the provision of non-
306 communicable diseases services in the Human Immunodeficiency Virus (HIV) and Sexually

307 Transmitted Diseases clinics and the use of existing patient follow-up mechanisms in managing
308 non-communicable diseases.

309 Predominantly, the cross-integration of services has shown significant improvements in
310 hypertension control. A cohort of patients in South Africa increased in controlled BP from 43%
311 before integration of services to 49% one year after integration [45]. Another cohort of patients
312 in Uganda and Tanzania had a 10% decline in the risk of uncontrolled BP [43]. In Uganda and
313 Kenya, the care for hypertension, diabetes, and HIV were integrated, and additional features of
314 care improved, leading to a 26% higher likelihood of initiating patients on hypertension
315 treatment and a 29% higher likelihood of BP control. In the Democratic Republic of the Congo,
316 hypertension services were integrated into Emergency Primary Clinic. While there was a high
317 rate of new hypertension diagnoses in 97% of the included sample, only 34% remained in care in
318 one year, and other those who remained in care, 71% achieved a systolic BP below 140 mmHg,
319 which is the cut-off used in the country for desired systolic BP [49].

320 In one instance, the hypertension clinic was built from scratch in Sierra Leone [46]. A cohort of
321 patients followed in that new rural hypertension clinic had BP control go from 6% at baseline to
322 31% at one year-follow-up [46].

323 **(7) Deliberate improvement in the quality of hypertension care**

324 Eight studies [31, 33, 36, 39, 40, 60, 61, 69] conducted in 5 countries explored the additional
325 value of deliberately gauging and improving systems for a better quality of hypertension care.

326 The quality improvement projects included an improved data recording process in Zambia and
327 Botswana [36, 69] and better monitoring through supervision in Cameroon [33] and South Africa
328 [31]. In South Africa, a quality improvement project on improving data recording and adherence
329 to treatment guidelines by providers was implemented through the introduction of a folded

330 guidelines sheet inside the patient file [31]. The project did not contribute to an increase in
331 patients with BP control, and providers reported that the project was overwhelming because of
332 staff shortage [31]. Where quality improvement was implemented jointly with other system
333 components such as improving the supply chain of equipment and consumables in Botswana
334 [69]; providers' training on hypertension care and task-shifting in Cameroon [33, 39]; supply
335 chain, training, and task-shifting in Zambia [36]; there were better blood pressure outcomes.

336 **Discussion**

337 This systematic review aimed to assess the health system factors and interventions for
338 hypertension awareness, initiation and adherence to hypertension treatment, and achievement of
339 controlled blood pressure in SSA. A 2013 systematic review in LMICs [27] and a 2015 narrative
340 synthesis in SSA [72] explored the health system determinants of hypertension care and reported
341 consistent findings of factors of hypertension outcomes: cost of care, human resources factors
342 such as adherence to protocols, physical resources factors such as lack of functioning equipment,
343 and lack of treatment guidelines. Our review identified the above and additional health system
344 interventions and factors, including the accessibility factors of care such as place and time of
345 care, the health facility type and capacity, the use of quality improvement strategies, and the
346 cross integration of services.

347 The healthcare provider's knowledge and adherence to hypertension treatment guidelines stood
348 out as one of the most studied health system interventions [40, 73, 74]. The capacity building
349 among healthcare providers and the task sharing and shifting of hypertension management roles
350 to vital professionals like nurses, pharmacists, and community health workers align with
351 scientific evidence from developing and developed countries [75, 76]. For instance, the nurses'

352 role in managing hypertension has evolved from merely measuring and monitoring blood
353 pressure to collaboratively detecting, diagnosing, and referring patients with hypertension and its
354 complications [77, 78]. In many countries and settings, nurses prescribe or dispense anti-
355 hypertensive medications, provide patient education and counseling to ensure medication
356 adherence, and assume leadership roles in spearheading quality improvement projects for better
357 management of hypertension [77]. An estimation of the global gap in clinic visits for
358 hypertension care reported that 50% of LMICs and 86% of lower-income countries have a
359 physician deficit even if patients were to make only three annual visits to the health facilities for
360 their hypertension [79]. Neupane and colleagues recommend shifting some hypertension
361 management tasks to non-physician clinicians to bridge that gap [79]. Interdisciplinary
362 collaboration is the way forward for SSA to provide quality hypertension care to patients;
363 however, regional and national policies must align with and support best practices.

364 The cross integration of hypertension services is another system-level intervention explored for
365 the management of hypertension. The hypertension services have been frequently integrated with
366 HIV clinics, and this strategy has demonstrated to be effective in helping patients achieve
367 controlled blood pressure in Sierra Leone [46], South Africa [45], and Tanzania and Uganda
368 [43], to name a few examples. There are some reasons why taking lessons from the management
369 of chronic infectious diseases could be effective in hypertension care. The management of
370 chronic infectious diseases, HIV and Tuberculosis, in resource-constrained settings has, despite
371 still-existing challenges, produced strong evidence and effective strategies for managing patients
372 with such complicated chronic health conditions amid, just to name a few; insufficient healthcare
373 professionals [80], inaccessibility of health services [81], and poor information management
374 systems [82]. In addition to demonstrating that task sharing with and task shifting to non-

375 physician healthcare providers is possible and effective [80, 83, 84], the process of managing
376 HIV and Tuberculosis has also demonstrated ways to manage loss to follow up by the use of
377 strong information management systems [82], decentralization of services close to the
378 community [85], and collaboration with community health workers [80, 84]; all the strategies
379 that could be well adapted to hypertension management. One of the information management
380 system strategies that have been effective in HIV and Tuberculosis control and hypertension
381 management in other low-income countries is the patient registries [86–89]. The current review
382 did not find studies exploring patient registries to prevent loss to follow-up in hypertension
383 management.

384 The hypertension clinics model consists of managing patients with hypertension in their own
385 outpatient unit and was experimented and proved effective in Sierra-Leone [46] and Eswatini
386 [58]. The premise of this strategy is to have well trained healthcare providers and good systems
387 of data management, in some instances to decentralize of hypertension care, and improvement in
388 patient follow-up. The lessons from the management of HIV and Tuberculosis could be applied
389 in those services. It is crucial to ensure that the detachment of hypertension care from the general
390 outpatient department or from the well-equipped hospital does not hamper the patients' initiation
391 on hypertension treatment through the internal transfer processes and that patients with
392 hypertension continue to receive holistic care for other health problems they might have in
393 addition to hypertension.

394 While the decentralization of care might address geographic barriers to hypertension care access,
395 other factors of accessibility such as cost of care and time of services require additional and
396 potentially different interventions. Extensively, the current and previous literature have shown
397 that the high direct and indirect costs of care hamper patients' use of health services and lead to

398 poor health outcomes and among patients with hypertension, poor blood pressure control [54, 66,
399 90]. The time of operation of clinics, though limited evidence exists, has an impact on the
400 staffing hence the long queues of patients at the in- and outpatient departments which
401 discourages patients' attendance to their appointments and encourages loss to follow-up [67, 91,
402 92]. Universal health coverage through government-subsidized insurance premiums has been
403 advocated as a solution to prevent catastrophic spending on healthcare services and associated
404 poor health outcomes [93–95], and the 24/7 hypertension clinic operation could be explored as a
405 potential intervention to the long waiting queues at the clinics. The financing of universal health
406 coverage and the 24/7 open clinics, however, require political buy-in and collaboration across
407 sectors, local and international [94].

408 While leadership and governance are central to the success of any endeavor to improve the
409 quality of care, their role and impact in advancing hypertension care in SSA are not widely
410 researched, and the few existing studies are predominantly of poor quality [96]. Thornton
411 highlighted the critical values of leadership commitment, willingness to fund care, strategic and
412 creative local and foreign partnerships, and evidence-based guidelines as the key reasons why
413 Botswana surpassed the United Nations' HIV management goals of 95% awareness, 95% on
414 treatment, and 95% [81]. A 3-year campaign mobilization on the role of clinical leaders in
415 hypertension management at various health systems in the United States achieved the goal of
416 80% blood pressure control within seven months [97]. A scoping review of interventions to
417 strengthen the health professionals' leadership in SSA found that the opportunities for leadership
418 development in SSA are scarce and those available are of poor quality and lacking a consistent
419 evaluation framework [98]. There is a need for more studies on strengthening leadership in
420 healthcare and exploring its impact on health outcomes, including hypertension in SSA.

421 As the burden of hypertension increases globally, the investment required of health systems to
422 manage hypertension is rising. Hypertension is significantly associated with adverse outcomes of
423 Coronavirus Disease 2019 (COVID-19), the ongoing pandemic ravaging the entire world's health
424 systems [99, 100]. Studies reported that hypertensive patients had almost three times the odds of
425 mortality compared to people without hypertension [99]. The long-term post-COVID symptoms
426 haunt the patients with hypertension who survive COVID-19 more than the general population
427 [101]. For instance, patients with hypertension are twice as likely to have migraine-like
428 headaches and 68% higher odds of poor sleep than people without hypertension [101]. Apart
429 from the COVID-19 rationale, under the Sustainable Development Goal (SDG) 3 (Ensure
430 healthy lives and promote well-being for all at all ages), target 3.4 aims to reduce by one-third
431 the premature mortality from non-communicable diseases [102]. The management of
432 hypertension, a significant risk factor for cardiovascular diseases, is a step closer to achieving
433 target 3.4 of SDG 3.

434 Standard tools for exploring the health system determinants for specific diseases are scarce in the
435 realm of hypertension care in Africa. There is a dire need for psychometric tools to explore
436 health system readiness to provide quality hypertension care. The availability of those tools
437 would open doors to researchers interested in hypertension care to gather quality data on health
438 system determinants and render the evidence to policymakers to develop policies directed at
439 shortfalls in care delivery to improve the health outcomes of patients with hypertension.

440 Future studies are recommended to explore the roles of leadership and governance and
441 information systems at the health facilities levels as well as multi-level approaches (ie,
442 individual, community, provider, health system) in the improvement of hypertension care [27,
443 72]. Additionally, while the current review explored studies conducted in SSA, most of the

444 studies were conducted in three countries (Ethiopia, South Africa, and Ghana). Future studies
445 should explore hypertension service readiness in other countries of SSA. The expansion of
446 studies exploring health system factors of hypertension care could be a way to highlight the areas
447 of need to advocate for support from local and international health agencies.

448 **Strengths and Limitations**

449 The strengths of the current review are the holistic view of health system factors and
450 interventions that affect the quality of hypertension service delivery, stringent critique of the
451 quality of the studies, and the overall derivation conclusion against the WHO framework [25].
452 Nevertheless, the current review included only studies published in English and did not include
453 the gray literature, which could consist of unpublished reports, and quality improvement projects
454 on the health system interventions to improve hypertension service delivery. While the review
455 attempted to isolate the effect of the individual health system factors, many system interventions
456 were delivered in a bundled approach which rendered the isolation impossible.

457 **Conclusion**

458 The literature exploring health system factors of hypertension outcomes in SSA is limited in
459 volume and quality. The combination of multiple health system interventions was likely to result
460 in better hypertension outcomes. More rigorously designed studies about the different aspects of
461 the health systems and their impact on hypertension outcomes, especially the health information
462 management and leadership and management are needed in SSA to inform effective
463 hypertension control efforts.

464

465 **List of abbreviations**

466 CINAHL: Cumulated Index to Nursing and Allied Health Literature

- 467 JBI: Joanna Briggs Institute
- 468 HIV: Human Immunodeficiency Virus
- 469 LMIC: Low- and Middle-Income Countries
- 470 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- 471 SARA: Service Availability and Readiness Assessment
- 472 SDG: Sustainable Development Goals
- 473 COVID-19: Coronavirus Disease 2019
- 474 SQUIRES: Standards for Quality Improvement Reporting Excellence
- 475 SSA: Sub-Saharan Africa
- 476 WHO: World Health Organization

477 **Declarations**

478 **Ethics approval and consent to participate**

479 The current study did not involve human subject research, and the ethical approval or consent to
480 participate is not applicable

481 **Consent for publication**

482 All authors reviewed and approved the final manuscript for publication

483 **Competing interest**

484 We have no conflict of interest to declare

485 **Funding**

486 Not applicable

487 **Authors' contributions**

488 SB: Idea conception, literature search, title, and abstract review, full-text review, quality

489 assessment, data extraction, analysis, and drafting of the manuscript

490 OO: Full-text review, quality assessment, manuscript drafting

491 FSS: Critical manuscript review, field expertise incorporation in the discussion of findings

492 YCM: Critical manuscript review, language editing, supervision

493 KA: Full-text review, quality assessment, data extraction, analysis, and revision of the

494 manuscript

495 CRH: Idea conception, design of literature search and inclusion and exclusion criteria, critical

496 manuscript review, language editing, supervision

497 **Acknowledgments**

498 We acknowledge the support of Stella Seal, the Library Informationist who helped in searching

499 the databases, Dr. Sarah Szanton and Dr. William E. Rosa for the contribution of ideas in project

500 ideation and discussion of findings, and Dr. Emmanuel Uwiringiyimana for the assistance in the

501 full-text screening.

502 **Authors' information**

503 **Samuel Byiringiro**

504 Ph.D. Candidate at Johns Hopkins University School of Nursing

505 525 N Wolfe St, Baltimore, Maryland, 21205

506 United States

507 **Oluwabunmi Ogungbe**

508 Post-doctoral fellow at Johns Hopkins University School of Nursing

509 525 N Wolfe St, Baltimore, Maryland, 21205

510 United States

511 **Yvonne Commodore-Mensah**

512 Associate Professor at Johns Hopkins University School of Nursing

513 525 N Wolfe St, Baltimore, Maryland, 21205

514 United States

515 **Khadijat Adeleye**

516 Ph.D. Student at the University of Massachusetts

517 Elaine Marieb College of Nursing

518 Amherst, Massachusetts, 01002

519 United States of America

520 **Fred Stephen Sarfo**

521 Professor of Medicine at Kwame Nkrumah University of Science & Technology, Department of

522 Medicine

523 Accra Rd, Kumasi, Ghana

524 Clinician at Komfo Anokye Teaching Hospital

525 Okomfo Anokye Road, Kumasi, Ghana

526

527 **Cheryl R. Himmelfarb**

528 Sarah E. Allison Endowed Professor and Vice Dean for Research, Johns Hopkins University

529 School of Nursing, Joint Appointments in Schools of Medicine and Public Health

530 525 N Wolfe St, Baltimore, Maryland, 21205

531 United States

532 **Supporting information**

533 Fig 1. PRISMA diagram with flowchart of study screening and inclusion

534 Fig 2. Distribution of studies on health system factors of hypertension care in Sub-Saharan
535 Africa

536
537 S-File 1. Search terms

538 S-File 3. PRISMA 2009 checklist

539 S-File 3. JBI Quality Assessment Results

540 S-File 4. Standards for Quality Improvement Reporting Excellence

541

542

543 **References**

- 544 [1] World Health Organization (WHO). Hypertension Facts Sheet,
545 <https://www.who.int/news-room/fact-sheets/detail/hypertension> (accessed 7 October
546 2020).
- 547 [2] Whelton PK, Carey RM, Aronow WS, et al. 2017
548 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
549 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *J*
550 *Am Coll Cardiol* 2018; 71: e127 LP-e248.
- 551 [3] Ataklte F, Erqou S, Kaptoge S, et al. Burden of undiagnosed hypertension in sub-saharan
552 Africa: a systematic review and meta-analysis. *Hypertension* 2015; 65: 291–298.
- 553 [4] Guwatudde D, Nankya-Mutyoba J, Kalyesubula R, et al. The burden of hypertension in
554 sub-Saharan Africa: A four-country cross sectional study. *BMC Public Health* 2015; 15:
555 1211.
- 556 [5] Desormais I, Amidou SA, Houehanou YC, et al. The prevalence, awareness, management
557 and control of hypertension in men and women in Benin, West Africa: The TAHES study.
558 *BMC Cardiovasc Disord* 2019; 19: 303.
- 559 [6] van de Vijver S, Akinyi H, Oti S, et al. Status report on hypertension in Africa -
560 Consultative review for the 6th Session of the African Union Conference of Ministers of
561 Health on NCD's. *Pan African Medical Journal* 2013; 16: 1937–8688.
- 562 [7] Twagirumukiza M, De Bacquer D, Kips JG, et al. Current and projected prevalence of
563 arterial hypertension in sub-Saharan Africa by sex, age and habitat: An estimate from
564 population studies. *Journal of Hypertension* 2011; 29: 1243–1252.
- 565 [8] Adinan J, Manongi R, Temu GA, et al. Preparedness of health facilities in managing
566 hypertension & diabetes mellitus in Kilimanjaro, Tanzania: a cross sectional study. *BMC*
567 *Health Serv Res* 2019; 19: 537.
- 568 [9] Deuboué Tchialeu RI, Yaya S, Labonté R. Health Systems Readiness to Manage the
569 Hypertension Epidemic in Primary Health Care Facilities in the Western Cape, South
570 Africa: A Study Protocol. *JMIR Res Protoc* 2016; 5: e35.
- 571 [10] Muthuri SK, Oti SO, Lilford RJ, et al. Salt reduction interventions in sub-Saharan Africa:
572 A systematic review. *PLoS ONE* 2016; 11: e0149680.
- 573 [11] Ireland DM, Clifton PM, Keogh JB. Achieving the Salt Intake Target of 6 g/Day in the
574 Current Food Supply in Free-Living Adults Using Two Dietary Education Strategies. *J*
575 *Am Diet Assoc* 2010; 110: 763–767.
- 576 [12] Adeyemo AA, Prewitt TE, Luke A, et al. The feasibility of implementing a dietary sodium
577 reduction intervention among free-living normotensive individuals in south west Nigeria.
578 *Ethn Dis* 2002; 12: 207–212.
- 579 [13] Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan
580 Africa: burden, risk and interventions. *Intern Emerg Med* 2016; 11: 299–305.
- 581 [14] Ogungbe O, Byiringiro S, Adedokun-Afolayan A, et al. Medication Adherence
582 Interventions for Cardiovascular Disease in Low-and Middle-Income Countries: A
583 Systematic Review. *Patient Prefer Adherence* 2021; 15: 885.
- 584 [15] Whelton PK, Williams B. The 2018 European Society of Cardiology/European Society of
585 Hypertension and 2017 American College of Cardiology/American Heart Association
586 Blood Pressure Guidelines: More Similar Than Different. *JAMA - Journal of the*
587 *American Medical Association* 2018; 320: 1749–1750.

- 588 [16] Armstrong C. JNC 8 guidelines for the management of hypertension in adults. *American*
589 *Family Physician* 2014; 90: 503–504.
- 590 [17] Dzudie A, Rayner B, Ojji D, et al. Roadmap to achieve 25% hypertension control in
591 Africa by 2025. *Cardiovasc J Afr* 2017; 28: 262–273.
- 592 [18] Jeemon P, Séverin T, Amodeo C, et al. World heart federation roadmap for hypertension –
593 A 2021 update. *Glob Heart* 2021; 16: 63.
- 594 [19] Nulu S, Aronow WS, Frishman WH. Hypertension in Sub-Saharan Africa: A Contextual
595 View of Patterns of Disease, Best Management, and Systems Issues. *Cardiol Rev* 2016;
596 24: 30–40.
- 597 [20] Wagner EH. Chronic disease management: what will it take to improve care for chronic
598 illness? *Effective clinical practice* □: *ECP* 1998; 1: 2–4.
- 599 [21] Crisp N. Health is made at home, hospitals are for repairs: Building a healthy and health-
600 creating society.
- 601 [22] World Health Organization (WHO). Service Availability and Readiness Assessment
602 (SARA): An annual monitoring system for service delivery - Reference Manual, Version
603 2.2. *Health Statistics and Information Systems* 2015; 175.
- 604 [23] Kozuki N, Oseni L, Mtimuni A, et al. Health facility service availability and readiness for
605 intrapartum and immediate postpartum care in Malawi: A cross-sectional survey. *PLoS*
606 *One*; 12. Epub ahead of print 1 March 2017. DOI: 10.1371/journal.pone.0172492.
- 607 [24] Kanyangarara M, Chou VB, Creanga AA, et al. Linking household and health facility
608 surveys to assess obstetric service availability, readiness and coverage: Evidence from 17
609 low- and middle-income countries. *J Glob Health*; 8. Epub ahead of print 2018. DOI:
610 10.7189/jogh.08.010603.
- 611 [25] WHO. Monitoring the Building Blocks of Health Systems □: a Handbook of Indicators
612 and. 2010; 110.
- 613 [26] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
614 meta-analyses: The PRISMA statement. *BMJ (Online)* 2009; 339: 332–336.
- 615 [27] Maimaris W, Paty J, Perel P, et al. The Influence of Health Systems on Hypertension
616 Awareness, Treatment, and Control: A Systematic Literature Review. *PLoS Med*; 10.
617 Epub ahead of print 2013. DOI: 10.1371/journal.pmed.1001490.
- 618 [28] Aromataris E and Munn Z. JBI Reviewer ’ s Manual. *The Joanna Briggs Institute* 2017;
619 32.
- 620 [29] Ogrinc G, Davies L, Goodman D, et al. SQUIRE 2.0 (Standards for QUality
621 Improvement Reporting Excellence): revised publication guidelines from a
622 detailed consensus process. *BMJ Quality & Safety* 2016; 25: 986 LP – 992.
- 623 [30] McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and
624 Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods*; n/a. Epub
625 ahead of print 26 April 2020. DOI: 10.1002/jrsm.1411.
- 626 [31] Steyn K, Lombard C, Gwebushe N, et al. Implementation of national guidelines,
627 incorporated within structured diabetes and hypertension records at primary level care in
628 Cape Town, South Africa: a randomised controlled trial. *Glob Health Action* 2013; 6:
629 20796.
- 630 [32] Goudge J, Chirwa T, Eldridge S, et al. Can lay health workers support the management of
631 hypertension? Findings of a cluster randomised trial in South Africa. *BMJ Glob Health*
632 2018; 3: e000577–e000577.

- 633 [33] Kingue S, Angandji P, Menanga AP, et al. Efficiency of an intervention package for
634 arterial hypertension comprising telemanagement in a Cameroonian rural setting: The
635 TELEMED-CAM study. *Pan Afr Med J* 2013; 15: 153.
- 636 [34] Ogedegbe G, Plange-Rhule J, Gyamfi J, et al. Health insurance coverage with or without a
637 nurse-led task shifting strategy for hypertension control: A pragmatic cluster randomized
638 trial in Ghana. *PLoS Med* 2018; 15: 1–17.
- 639 [35] Hickey MD, Ayieko J, Owaraganise A, et al. Effect of a patient-centered hypertension
640 delivery strategy on all-cause mortality: Secondary analysis of SEARCH, a community-
641 randomized trial in rural Kenya and Uganda. *PLoS Med* 2021; 18.
- 642 [36] Yan LD, Chirwa C, Chi BH, et al. Hypertension management in rural primary care
643 facilities in Zambia: a mixed methods study. *BMC Health Serv Res* 2017; 17: 111.
- 644 [37] Hendriks ME, Wit FWNMM, Akande TM, et al. Effect of health insurance and facility
645 quality improvement on blood pressure in adults with hypertension in Nigeria: a
646 population-based study. *JAMA Intern Med* 2014; 174: 555–563.
- 647 [38] Nelissen HE, Cremers AL, Okwor TJ, et al. Pharmacy-based hypertension care employing
648 mHealth in Lagos, Nigeria - a mixed methods feasibility study. *BMC Health Serv Res*
649 2018; 18: 934.
- 650 [39] Labhardt ND, Balo J-R, Ndam M, et al. Task shifting to non-physician clinicians for
651 integrated management of hypertension and diabetes in rural Cameroon: a programme
652 assessment at two years. *BMC Health Serv Res* 2010; 10: 339.
- 653 [40] Ogola EN, Okello FO, Herr JL, et al. Healthy Heart Africa-Kenya: A 12-Month
654 Prospective Evaluation of Program Impact on Health Care Providers' Knowledge and
655 Treatment of Hypertension. *Glob Heart* 2019; 14: 61–70.
- 656 [41] Zou G, Witter S, Caperon L, et al. Adapting and implementing training, guidelines and
657 treatment cards to improve primary care-based hypertension and diabetes management in
658 a fragile context: results of a feasibility study in Sierra Leone. *BMC Public Health* 2020;
659 20: 1185.
- 660 [42] Berhe DF, Taxis K, Haaijer-Ruskamp FM, et al. Hypertension treatment practices and its
661 determinants among ambulatory patients: retrospective cohort study in Ethiopia. *BMJ*
662 *Open* 2017; 7: e015743–e015743.
- 663 [43] Birungi J, Kivuyo S, Garrib A, et al. Integrating health services for HIV infection,
664 diabetes and hypertension in sub-Saharan Africa: a cohort study. *BMJ Open* 2021; 11:
665 e053412-.
- 666 [44] Miselli MA, Cavallin F, Marwa S, et al. An integrated management system for
667 noncommunicable diseases program implementation in a sub-saharan setting. *Int J*
668 *Environ Res Public Health* 2021; 18.
- 669 [45] Gausi B, Berkowitz N, Jacob N, et al. Treatment outcomes among adults with HIV/non-
670 communicable disease multimorbidity attending integrated care clubs in Cape Town,
671 South Africa. *AIDS Res Ther* 2021; 18: 72.
- 672 [46] Kachimanga C, Dibba Y, Patiño M, et al. Implementation of a non-communicable disease
673 clinic in rural Sierra Leone: early experiences and lessons learned. *J Public Health Policy*
674 2021; 42: 422–438.
- 675 [47] Otieno HA, Miezah C, Yonga G, et al. Improved blood pressure control via a novel
676 chronic disease management model of care in sub-Saharan Africa: Real-world program
677 implementation results. *J Clin Hypertens* 2021; 23: 785–792.

- 678 [48] Vedanthan R, Kumar A, Kamano JH, et al. Effect of nurse-based management of
679 hypertension in Rural Western Kenya. *Glob Heart* 2020; 15.
- 680 [49] Ratnayake R, Wittcoff A, Majaribu J, et al. Early experiences in the integration of non-
681 communicable diseases into emergency primary health care, beni region, democratic
682 republic of the Congo. *Ann Glob Health* 2021; 87.
- 683 [50] Asgedom SW, Atey TM, Desse TA. Antihypertensive medication adherence and
684 associated factors among adult hypertensive patients at Jimma University Specialized
685 Hospital, southwest Ethiopia. *BMC Res Notes* 2018; 11: 27.
- 686 [51] Ambaw AD, Alemie GA, W/Yohannes SM, et al. Adherence to antihypertensive
687 treatment and associated factors among patients on follow up at University of Gondar
688 Hospital, Northwest Ethiopia. *BMC Public Health* 2012; 12: 282.
- 689 [52] Mekonnen HS, Gebrie MH, Eyasu KH, et al. Drug adherence for antihypertensive
690 medications and its determinants among adult hypertensive patients attending in chronic
691 clinics of referral hospitals in Northwest Ethiopia. *BMC Pharmacol Toxicol* 2017; 18: 27.
- 692 [53] Akunne OO, Adedapo ADA. Antihypertensive prescription among black patients without
693 compelling indications: prescription, effectiveness, quality and cost of medication. *BMC*
694 *Health Serv Res* 2019; 19: 373.
- 695 [54] Adedapo ADA, Sikuade O, Adeleke S, et al. Drug utilization and blood pressure control in
696 a population where antihypertensives are given free: effect of policy change. *Afr J Med*
697 *Med Sci* 2012; 41: 349–356.
- 698 [55] Gala P, Moshokgo V, Seth B, et al. Medication Errors and Blood Pressure Control Among
699 Patients Managed for Hypertension in Public Ambulatory Care Clinics in Botswana. *J Am*
700 *Heart Assoc* 2020; 9: 1–10.
- 701 [56] Lulebo AM, Kaba DK, Atake SE-H, et al. Task shifting in the management of
702 hypertension in Kinshasa, Democratic Republic of Congo: a cross-sectional study. *BMC*
703 *Health Serv Res* 2017; 17: 698.
- 704 [57] Mlawanda G, Pather M, Govender S. An analysis of blood pressure measurement in a
705 primary care hospital in Swaziland. *Afr J Prim Health Care Fam Med* 2014; 6: E1–E9.
- 706 [58] Sharp A, Riches N, Mims A, et al. Decentralising NCD management in rural southern
707 Africa: evaluation of a pilot implementation study. *BMC Public Health* 2020; 20: 44.
- 708 [59] Mashozhera S, Bamitale SK, Godman B, et al. Compliance to hypertensive prescribing
709 guidelines and blood pressure control in elderly patients in Namibia: Findings and
710 implications. *Journal of Pharmaceutical Health Services Research* 2021; 12: 53–60.
- 711 [60] Ameh S. Evaluation of an integrated HIV and hypertension management model in rural
712 south africa: a mixed methods approach. *Glob Health Action* 2020; 13: 1750216.
- 713 [61] Pfister C-L, Govender S, Dyer RA, et al. A multicenter, cross-sectional quality
714 improvement project: The perioperative implementation of a hypertension protocol by
715 anesthesiologists. *Anesth Analg* 2020; 1401–1408.
- 716 [62] Pillay S, Pillay D, Pillay RS. The burden of hypertension in KwaZulu-Natal Province,
717 South Africa: A 6-year perspective. *South African Medical Journal* 2021; 111: 159–165.
- 718 [63] Harrison MA, Marfo AFA, Opare-Addo MNA, et al. Anti-hypertensive medication access
719 and affordability and their association with blood pressure control at a teaching hospital in
720 ghana. *Pan African Medical Journal* 2021; 39.
- 721 [64] Menyau EK, Corso B, Minicuci N, et al. Determinants of change in blood pressure in
722 Ghana: Longitudinal data from WHO-SAGE Waves 1-3. *PLoS One* 2021; 16.

- 723 [65] Sarfo FS, Ovbiagele B. Apparent Treatment Resistant Hypertension Among Stroke
724 Survivors in Ghana. *Journal of Stroke and Cerebrovascular Diseases* 2020; 29.
- 725 [66] Adomako NO, Marfo AFA, Opare-Addo MNA, et al. Blood Pressure Control,
726 Accessibility, and Adherence to Antihypertensive Medications: Patients Seeking Care in
727 Two Hospitals in the Ashanti Region of Ghana. *Int J Hypertens* 2021; 2021.
- 728 [67] Kuria N, Reid A, Owiti P, et al. Compliance with follow-up and adherence to medication
729 in hypertensive patients in an urban informal settlement in Kenya: comparison of three
730 models of care. *Trop Med Int Health* 2018; 23: 785–794.
- 731 [68] Mbau L, Harrison R, Kizito W, et al. Case identification, retention and blood pressure
732 control in Kenya. *Public Health Action* 2022; 12: 58–63.
- 733 [69] Kande C, Mash R. Improving the quality of care for patients with hypertension in
734 Moshupa District, Botswana: quality improvement cycle. *Afr J Prim Health Care Fam*
735 *Med* 2014; 6: E1–E4.
- 736 [70] Mbui JM, Oluka MN, Guantai EM, et al. Prescription patterns and adequacy of blood
737 pressure control among adult hypertensive patients in Kenya; findings and implications.
738 *Expert Rev Clin Pharmacol* 2017; 10: 1263–1271.
- 739 [71] Folb N, Bachmann MO, Bateman ED, et al. Socioeconomic and modifiable predictors of
740 blood pressure control for hypertension in primary care attenders in the Western Cape,
741 South Africa. *S Afr Med J* 2016; 106: 1241–1246.
- 742 [72] Iwelunmor J, Plange-Rhule J, Airhihenbuwa CO, et al. A Narrative Synthesis of the
743 Health Systems Factors Influencing Optimal Hypertension Control in Sub-Saharan Africa.
744 *PLoS One* 2015; 10: e0130193–e0130193.
- 745 [73] Brunström M, Ng N, Dahlström J, et al. Association of Physician Education and Feedback
746 on Hypertension Management With Patient Blood Pressure and Hypertension Control.
747 *JAMA Netw Open* 2020; 3: e1918625–e1918625.
- 748 [74] Abegaz TM, Tefera YG, Befekadu Abebe T. Target Organ Damage and the Long Term
749 Effect of Nonadherence to Clinical Practice Guidelines in Patients with Hypertension: A
750 Retrospective Cohort Study. *Int J Hypertens* 2017; 1–8.
- 751 [75] Di Palo KE, Kish T. The role of the pharmacist in hypertension management. *Curr Opin*
752 *Cardiol* 2018; 33: 382–387.
- 753 [76] Gyamfi J, Plange-Rhule J, Iwelunmor J, et al. Training nurses in task-shifting strategies
754 for the management and control of hypertension in Ghana: a mixed-methods study. *BMC*
755 *Health Serv Res* 2017; 17: 1–9.
- 756 [77] Himmelfarb CRD, Commodore-Mensah Y, Hill MN. Expanding the Role of Nurses to
757 Improve Hypertension Care and Control Globally. *Ann Glob Health* 2016; 82: 243–253.
- 758 [78] Odonkor ST, Frimpong K. Burnout among Healthcare Professionals in Ghana: A Critical
759 Assessment. *Biomed Res Int* 2020; 2020: 1614968.
- 760 [79] Neupane D, Gao Y, Feng Y, et al. Estimation of the Global Gap in Clinic Visits for
761 Hypertension Care between Patient Need and Physician Capacity. *Hypertension* 2021;
762 779–786.
- 763 [80] Peresu E, Heunis JC, Kigozi NG, et al. Task-shifting directly observed treatment and
764 multidrug-resistant tuberculosis injection administration to lay health workers: stakeholder
765 perceptions in rural Eswatini. *Hum Resour Health*; 18. Epub ahead of print 1 December
766 2020. DOI: 10.1186/S12960-020-00541-4.
- 767 [81] Thornton J. Botswana’s HIV/AIDS success. *The Lancet* 2022; 400: 480–481.

- 768 [82] Fraser HSFF, Allen C, Bailey C, et al. Information systems for patient follow-up and
769 chronic management of HIV and tuberculosis: a life-saving technology in resource-poor
770 areas. *J Med Internet Res* 2007; 9: e29–e29.
- 771 [83] Suzan-Monti M, Blanche J, Boyer S, et al. Benefits of task-shifting HIV care to nurses in
772 terms of health-related quality of life in patients initiating antiretroviral therapy in rural
773 district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA
774 (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau
775 (ESTHER) substudy]. *HIV Med* 2015; 16: 307–318.
- 776 [84] Busza J, Dauya E, Bandason T, et al. The role of community health workers in improving
777 HIV treatment outcomes in children: lessons learned from the ZENITH trial in Zimbabwe.
778 *Health Policy Plan* 2018; 33: 328–334.
- 779 [85] Loubiere S, Boyer S, Protopopescu C, et al. Decentralization of HIV care in Cameroon:
780 Increased access to antiretroviral treatment and associated persistent barriers. *Health
781 Policy (New York)* 2009; 92: 165–173.
- 782 [86] Lancet T. National disease registries for advancing health care. *The Lancet* 2011; 378:
783 2050.
- 784 [87] O’Brien E. How Registries Can Guide Our Future? *Hypertension* 2017; 69: 198–199.
- 785 [88] Myanganbayar M, Baatarsuren U, Chen G, et al. Hypertension knowledge, attitudes, and
786 practices of nurses and physicians in primary care in Ulaanbaatar Mongolia. *J Clin
787 Hypertens* 2019; 21: 1202–1209.
- 788 [89] Chan BTB, Rauscher C, Issina AM, et al. A programme to improve quality of care for
789 patients with chronic diseases, Kazakhstan. *Bull World Health Organ* 2020; 98: 161–169.
- 790 [90] Gnugesser E, Chwila C, Brenner S, et al. The economic burden of treating uncomplicated
791 hypertension in Sub-Saharan Africa: a systematic literature review. *BMC Public Health*
792 2022; 22: 1507.
- 793 [91] Wagenaar BH, Gimbel S, Hoek R, et al. Wait and consult times for primary healthcare
794 services in central Mozambique: a time-motion study. *Glob Health Action*; 9. Epub ahead
795 of print 1 December 2016. DOI: 10.3402/GHA.V9.31980.
- 796 [92] Son YJ, Lee EK, Ko Y. Association of Working Hours and Patient Safety Competencies
797 with Adverse Nurse Outcomes: A Cross-Sectional Study. *Int J Environ Res Public Health*;
798 16. Epub ahead of print 1 November 2019. DOI: 10.3390/IJERPH16214083.
- 799 [93] de Maeseneer J, Li D, Palsdottir B, et al. Universal health coverage and primary health
800 care: the 30 by 2030 campaign. *Bull World Health Organ* 2020; 98: 812.
- 801 [94] Greer SL, Méndez CA. Universal Health Coverage: A Political Struggle and Governance
802 Challenge. *Am J Public Health* 2015; 105: S637.
- 803 [95] American Public Health Association. The Importance of Universal Health Care in
804 Improving Our Nation’s Response to Pandemics and Health Disparities,
805 [https://www.apha.org/Policies-and-Advocacy/Public-Health-Policy-Statements/Policy-
806 Database/2021/01/14/The-Importance-of-Universal-Health-Care-in-Improving-Response-
807 to-Pandemics-and-Health-Disparities](https://www.apha.org/Policies-and-Advocacy/Public-Health-Policy-Statements/Policy-Database/2021/01/14/The-Importance-of-Universal-Health-Care-in-Improving-Response-to-Pandemics-and-Health-Disparities) (accessed 18 August 2022).
- 808 [96] Johnson O, Begg K, Kelly AH, et al. Interventions to strengthen the leadership capabilities
809 of health professionals in Sub-Saharan Africa: a scoping review. *Health Policy Plan* 2021;
810 36: 117–133.
- 811 [97] Lustig A, Ogden M, Brenner RW, et al. The Central Role of Physician Leadership for
812 Driving Change in Value-Based Care Environments. *J Manag Care Spec Pharm* 2016; 22:
813 1116–1122.

- 814 [98] Johnson O, Begg K, Kelly AH, et al. Interventions to strengthen the leadership capabilities
815 of health professionals in Sub-Saharan Africa: a scoping review. *Health Policy Plan* 2021;
816 36: 117–133.
- 817 [99] Liang X, Shi L, Wang Y, et al. The association of hypertension with the severity and
818 mortality of COVID-19 patients: Evidence based on adjusted effect estimates. *J Infect*
819 2020; 81: e44–e47.
- 820 [100] de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID
821 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.
822 *Diabetol Metab Syndr* 2020; 12: 75.
- 823 [101] Fernández-de-las-Peñas C, Torres-Macho J, Velasco-Arribas M, et al. Preexisting
824 hypertension is associated with a greater number of long-term post-COVID symptoms and
825 poor sleep quality: a case–control study. *Journal of Human Hypertension* 2022 36:6 2022;
826 36: 582–584.
- 827 [102] United Nations. Department of Economic and Social Affairs | Sustainable Development
828 Goals, <https://sdgs.un.org/goals/goal3> (2020, accessed 4 November 2020).
829
830

Identification and screening of studies for inclusion

Identification

Records identified from databases
(n=7494)

Duplicates (n= 3121)

Records screened by title or title
and abstract
(n=4373)

Irrelevant (n=4168)

Records screened by full-text
review
(n=205)

**Excluded after full-text review
(n=166)**

Descriptive studies (n=70)

Lack of eligible hypertension
outcome (n=27)

Ineligible intervention/
factor (n=4)

Full text unavailable (n=16)

Ineligible study design (n=30)

Not in clinical setting (n=11)

Conducted outside SSA (n=2)

Conference report (n=1)

Systematic review (n=4)

Critical risk of bias (n=1)

Studies included in the review
(n=39)

Screening

Included

